View Financial HealthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsCheilbio 배당 및 자사주 매입배당 기준 점검 0/6Cheilbio 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률-5.1%자사주 매입 수익률총 주주 수익률-5.1%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트공시 • Apr 13Cheilbio Co., Ltd. (KOSDAQ:A052670) announces an Equity Buyback for KRW 3,000 million worth of its shares.Cheilbio Co., Ltd. (KOSDAQ:A052670) announces a share repurchase program. Under the program, the company will repurchase up to KRW 3,000 million worth of its own shares pursuant to a contract with Samsung Securities Co., Ltd. The purpose of the buyback is to enhance shareholder value and to stabilize stock price. The plan will be valid up to October 11, 2022. As of April 11, 2022, the company had 870,936 shares in treasury within scope available for dividend and had no shares in treasury through other repurchase.모든 업데이트 보기Recent updatesBoard Change • Feb 10Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.공시 • Mar 14Cheilbio Co., Ltd., Annual General Meeting, Mar 31, 2025Cheilbio Co., Ltd., Annual General Meeting, Mar 31, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 131, sandan-ro 83beon-gil, danwon-gu, gyeonggi-do, ansan South Korea공시 • Sep 26Cheilbio Co., Ltd. (KOSDAQ:A052670) signed a letter of intent to acquire Sungshin Bio Co., Ltd. from Kim Moon-ja and others.Cheilbio Co., Ltd. (KOSDAQ:A052670) signed a letter of intent to acquire Sungshin Bio Co., Ltd. from Kim Moon-ja and others on September 25, 2024. Agreement is expected to be signed on September 27, 2024, and expected completion of the transaction is December 1, 2024.Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.공시 • Apr 13Cheilbio Co., Ltd. (KOSDAQ:A052670) announces an Equity Buyback for KRW 3,000 million worth of its shares.Cheilbio Co., Ltd. (KOSDAQ:A052670) announces a share repurchase program. Under the program, the company will repurchase up to KRW 3,000 million worth of its own shares pursuant to a contract with Samsung Securities Co., Ltd. The purpose of the buyback is to enhance shareholder value and to stabilize stock price. The plan will be valid up to October 11, 2022. As of April 11, 2022, the company had 870,936 shares in treasury within scope available for dividend and had no shares in treasury through other repurchase.Valuation Update With 7 Day Price Move • Mar 22Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₩2,300, the stock trades at a trailing P/E ratio of 36.3x. Average trailing P/E is 24x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 15% over the past three years.Valuation Update With 7 Day Price Move • Jan 27Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to ₩2,450, the stock trades at a trailing P/E ratio of 38.7x. Average trailing P/E is 21x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 5.4% over the past three years.분석 기사 • Mar 15A Look At The Intrinsic Value Of Cheilbio Co., Ltd. (KOSDAQ:052670)In this article we are going to estimate the intrinsic value of Cheilbio Co., Ltd. ( KOSDAQ:052670 ) by taking the...Is New 90 Day High Low • Feb 20New 90-day low: ₩6,700The company is down 19% from its price of ₩8,270 on 20 November 2020. The South Korean market is up 19% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 4.0% over the same period.Is New 90 Day High Low • Jan 28New 90-day low: ₩7,250The company is down 7.0% from its price of ₩7,770 on 30 October 2020. The South Korean market is up 32% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 13% over the same period.분석 기사 • Jan 21Can You Imagine How Cheilbio's (KOSDAQ:052670) Shareholders Feel About The 83% Share Price Increase?By buying an index fund, investors can approximate the average market return. But if you buy good businesses at...Is New 90 Day High Low • Dec 28New 90-day low: ₩7,410The company is down 3.0% from its price of ₩7,650 on 29 September 2020. The South Korean market is up 20% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 15% over the same period.분석 기사 • Nov 29Estimating The Intrinsic Value Of Cheilbio Co., Ltd. (KOSDAQ:052670)In this article we are going to estimate the intrinsic value of Cheilbio Co., Ltd. (KOSDAQ:052670) by taking the...Is New 90 Day High Low • Sep 24New 90-day low: ₩7,070The company is down 10.0% from its price of ₩7,880 on 26 June 2020. The South Korean market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 23% over the same period.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 A052670 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: A052670 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Cheilbio 배당 수익률 vs 시장A052670의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (A052670)n/a시장 하위 25% (KR)1.4%시장 상위 25% (KR)4.4%업계 평균 (Pharmaceuticals)1.1%분석가 예측 (A052670) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 A052670 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 A052670 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 A052670 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: A052670 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YKR 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/02/22 01:03종가2026/02/20 00:00수익2025/09/30연간 수익2024/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Cheilbio Co., Ltd.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • Apr 13Cheilbio Co., Ltd. (KOSDAQ:A052670) announces an Equity Buyback for KRW 3,000 million worth of its shares.Cheilbio Co., Ltd. (KOSDAQ:A052670) announces a share repurchase program. Under the program, the company will repurchase up to KRW 3,000 million worth of its own shares pursuant to a contract with Samsung Securities Co., Ltd. The purpose of the buyback is to enhance shareholder value and to stabilize stock price. The plan will be valid up to October 11, 2022. As of April 11, 2022, the company had 870,936 shares in treasury within scope available for dividend and had no shares in treasury through other repurchase.
Board Change • Feb 10Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
공시 • Mar 14Cheilbio Co., Ltd., Annual General Meeting, Mar 31, 2025Cheilbio Co., Ltd., Annual General Meeting, Mar 31, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 131, sandan-ro 83beon-gil, danwon-gu, gyeonggi-do, ansan South Korea
공시 • Sep 26Cheilbio Co., Ltd. (KOSDAQ:A052670) signed a letter of intent to acquire Sungshin Bio Co., Ltd. from Kim Moon-ja and others.Cheilbio Co., Ltd. (KOSDAQ:A052670) signed a letter of intent to acquire Sungshin Bio Co., Ltd. from Kim Moon-ja and others on September 25, 2024. Agreement is expected to be signed on September 27, 2024, and expected completion of the transaction is December 1, 2024.
Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
공시 • Apr 13Cheilbio Co., Ltd. (KOSDAQ:A052670) announces an Equity Buyback for KRW 3,000 million worth of its shares.Cheilbio Co., Ltd. (KOSDAQ:A052670) announces a share repurchase program. Under the program, the company will repurchase up to KRW 3,000 million worth of its own shares pursuant to a contract with Samsung Securities Co., Ltd. The purpose of the buyback is to enhance shareholder value and to stabilize stock price. The plan will be valid up to October 11, 2022. As of April 11, 2022, the company had 870,936 shares in treasury within scope available for dividend and had no shares in treasury through other repurchase.
Valuation Update With 7 Day Price Move • Mar 22Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₩2,300, the stock trades at a trailing P/E ratio of 36.3x. Average trailing P/E is 24x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 15% over the past three years.
Valuation Update With 7 Day Price Move • Jan 27Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to ₩2,450, the stock trades at a trailing P/E ratio of 38.7x. Average trailing P/E is 21x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 5.4% over the past three years.
분석 기사 • Mar 15A Look At The Intrinsic Value Of Cheilbio Co., Ltd. (KOSDAQ:052670)In this article we are going to estimate the intrinsic value of Cheilbio Co., Ltd. ( KOSDAQ:052670 ) by taking the...
Is New 90 Day High Low • Feb 20New 90-day low: ₩6,700The company is down 19% from its price of ₩8,270 on 20 November 2020. The South Korean market is up 19% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 4.0% over the same period.
Is New 90 Day High Low • Jan 28New 90-day low: ₩7,250The company is down 7.0% from its price of ₩7,770 on 30 October 2020. The South Korean market is up 32% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 13% over the same period.
분석 기사 • Jan 21Can You Imagine How Cheilbio's (KOSDAQ:052670) Shareholders Feel About The 83% Share Price Increase?By buying an index fund, investors can approximate the average market return. But if you buy good businesses at...
Is New 90 Day High Low • Dec 28New 90-day low: ₩7,410The company is down 3.0% from its price of ₩7,650 on 29 September 2020. The South Korean market is up 20% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 15% over the same period.
분석 기사 • Nov 29Estimating The Intrinsic Value Of Cheilbio Co., Ltd. (KOSDAQ:052670)In this article we are going to estimate the intrinsic value of Cheilbio Co., Ltd. (KOSDAQ:052670) by taking the...
Is New 90 Day High Low • Sep 24New 90-day low: ₩7,070The company is down 10.0% from its price of ₩7,880 on 26 June 2020. The South Korean market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 23% over the same period.